PATENT CLAIM ANALYSIS

Application Number: 15956232
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-09
Patent Classification: ["514", "574000"]

Abstract:
Methods for the treatment of homozygous familial hypercholesterolemia, compound heterozygous familial hypercholesterolemia, or heterozygous familial hypercholesterolemia by administering gemcabene as an adjunct to other lipid lowering therapy and/or modified diet.

Claim (Index 57):
The method of  claim 49 , wherein the lipid-lowering therapy comprises administration of a cholesterol absorption inhibitor, a HMG-CoA reductase inhibitor, a PCSK9 inhibitor, an ACC inhibitor, an ApoC-III inhibitor, an Apo E mimetic, an Apo B synthesis inhibitor, a microsomal triglyceride transfer protein inhibitor, an ACL-inhibitor, fish oil, EPA, Lovaza, an ethyl ester of eicosapentaenoic acid, docosahexaenoic acid, an ethyl ester of docosahexaenoic acid, nicotinic acid, bile acid sequestrant, a CETP inhibitor or any combination thereof.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 91.0
- Lexical Diversity: 1.22222
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14801384', '14539199', '13982373', '13982381', '14370722']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7799289009332839
- 35 USC 102 Novelty (BERT): 0.5543063189634435
- Combined Prediction Score: 0.7573666427362999
- Mean Citation Score: 376.79971600000016
- Max Citation Score: 447.5305
- Similarity Product: 295.82945677942035

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test